Holen Sie sich die Stockscreener-App
22.87
1.87%
0.42
Handel nachbörslich:
22.91
0.04
+0.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical Inc. Class Action: Levi & - GlobeNewswire
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. - GlobeNewswire
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm - GlobeNewswire Inc.
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - 巴士的報
FinancialContentRARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - markets.financialcontent.com
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - Finansavisen
RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Norfolk Daily News
Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - Finansavisen
Aberdeen Group plc Buys 496,295 Shares of Ultragenyx Pharmaceutical Inc. $RARE - marketbeat.com
Ultragenyx Pharmaceutical Hits 52-Week Low at $18.29 Amidst Declining Performance - Markets Mojo
RARE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire
Ultragenyx says gene therapy accepted for FDA review again - MSN
Ultragenyx EVP Pinion sells $228k in shares - Investing.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
Ultragenyx Faces Lawsuit Deadline for Investor Losses - National Today
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of - PharmiWeb.com
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - The AI Journal
Rosen Law Firm Urges Ultragenyx Shareholders to File Claims - National Today
Mereo BioPharma Faces Deadline for Shareholder Vote - National Today
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ - marketscreener.com
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) - Bitget
ULTRAGENYX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important April 6 Deadline in Securities Class ActionRARE - ACCESS Newswire
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Re - GuruFocus
FDA accepts Ultragenyx gene therapy application for rare disease By Investing.com - Investing.com Australia
Ultragenyx CFO Horn Howard sells $98k in shares By Investing.com - Investing.com India
Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,683 Shares of Stock - MarketBeat
Ultragenyx (RARE) CFO sells 4,683 shares, retains 80,351 stake - stocktitan.net
ULTRAGENYX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
Morgan Stanley reiterates Ultragenyx stock rating on FDA filing progress By Investing.com - za.investing.com
Morgan Stanley reiterates Ultragenyx stock rating on FDA filing progress - Investing.com
Ultragenyx (RARE) Moves Forward with FDA Review of Gene Therapy Application - gurufocus.com
Pomerantz LLP Notifies Investors of Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. – RARE - ACCESS Newswire
Leerink reiterates Ultragenyx stock rating on gene therapy progress - Investing.com
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA - The Chronicle-Journal
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx BLA for UX111 Accepted for FDA Review - TipRanks
If regulatory approval is obtained, production of the gene therapy UX111 by Ultragenyx Pharmaceutical Inc (RARE) will take place in the United States, with plans to proceed simultaneously at both Andelyn Biosciences and Ultragenyx's own facilities. - Bitget
Ultragenyx resubmitted BLA for UX111 accepted with PDUFA date set for Sept. 19, 2026 - TradingView
FDA accepts Ultragenyx gene therapy application for rare disease - Investing.com
Ultragenyx (RARE) gets FDA review date for UX111 gene therapy on Sept. 19, 2026 - stocktitan.net
FDA starts review of Ultragenyx gene therapy for fatal child disease - stocktitan.net
Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT - MSN
Howard Horn sells multiple RARE shares (NASDAQ: RARE) under Form 144 - Stock Titan
Ultragenyx Pharmaceutical Inc. (RARE): A bull case theory - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Ultragenyx LawsuitRARE - prnewswire.com
Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study - Insider Monkey
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):